Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 25 Mar 2013 |
| Genmab A/S Summons Annual General Meeting | 19 Mar 2013 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 13 Mar 2013 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 13 Mar 2013 |
| Articles of Association for Genmab A/S | 13 Mar 2013 |